Midostaurin, an flt-3 inhibitor with a broad kinase inhibition dendrogram, increases OS in AML patients (when added to daunorubicin and cytarabine) [86], yet does not hamper TCR signaling or T-cell activation [87]. The gene discussed is FLT3; the disease is acute myeloid leukemia.